Serna Bio GTM brain

Serna Bio develops RNA-targeting small molecules and partners with biopharma teams on difficult drug targets.

category

RNA-targeted drug discovery

market profile

  • text: Drug discovery teams seek approaches to disease biology that conventional protein-centric small molecules cannot readily address.
  • text: Serna combines an internal preclinical pipeline with external discovery collaborations.

personas

  • title: Head of drug discovery
    pains:
    • Validated disease biology may lack a druggable protein binding site.
    • RNA-targeted discovery requires specialized structural and ligand data.
  • title: Biopharma business development and licensing lead
    pains:
    • Needs differentiated external programs and credible platform partners.
    • Must evaluate scientific evidence and partnership economics before committing resources.
  • title: RNA biology or medicinal chemistry leader
    pains:
    • Optimizing selectivity and potency for RNA-ligand interactions is experimentally demanding.
    • Existing datasets may not sufficiently cover functional RNA pockets.

icp

  • text: Pharmaceutical and biotechnology companies with disease expertise and hard-to-drug targets, including respiratory disease programs.
  • text: R&D organizations capable of entering discovery collaborations or licensing preclinical programs; company size is not specified.

message pillars

  • text: Control disease-relevant protein expression via RNA.
  • text: Use a platform designed for RNA discovery.
  • text: Pursue targets beyond conventional approaches.

objections

  • objection: Can RNA-targeted molecules achieve selectivity and developability?
    response: Review experimental data and target-specific validation with Serna; discovery claims are preclinical and require independent assessment.
  • objection: Why partner rather than build an internal platform?
    response: Assess whether Serna's RNA pocket and interaction datasets complement the team's disease expertise and justify a scoped collaboration.

competitors

  • name: Envisagenics
    why: Uses RNA biology and AI for therapeutic discovery, competing for biopharma discovery partnerships.
  • name: Silence Therapeutics
    why: Develops RNA-targeting medicines through a different modality, competing for targets and partnerships.

influencers

  • name: Rabia Khan
    url: https://www.concordia.ca/cunews/offices/advancement/2025/07/23/great-concordian-rabia-khan-founder-and-ceo-of-serna-bio.html
    why: Founder and CEO explaining the company's RNA discovery approach.

keywords

  • RNA targeted small molecules
  • RNA drug discovery platform
  • undruggable targets RNA
  • RNA ligand discovery
  • RNA splicing small molecule
  • biopharma discovery partnership

voice

  • scientific
  • ambitious
  • platform-oriented

signals

  • text: A drug discovery team has a validated target that proved difficult to address with protein-directed approaches.
  • text: A biopharma company is seeking external discovery collaborations in respiratory or other high-unmet-need disease areas.

stack

  • machine learning

pricing

model: unknown

motion

sales_led

channels

  • scientific publications
  • industry conferences
  • partnerships
  • website

confidence

medium

Founders

  • name: Rabia Khan
    title: Founder
    role: Founder
    bio: Currently working on drugging RNA with small molecules. Previously built the ML team at Sensyne Health (UK PLC) // and worked at BenevolentAI. Love working at the intersection of biology / technology / business. Foodie at heart.

Back to YC companies